ZOSUQUIDAR TRIHYDROCHLORIDE IN NEWLY DIAGNOSED AML

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究结束了。（来自www.cancer.gov网站）化疗中使用的药物通过不同的方式阻止癌细胞分裂，从而使它们停止生长或死亡。盐酸佐舒魁德可能通过使癌细胞对药物更敏感来帮助柔红霉素和阿糖胞苷杀死更多的癌细胞。柔红霉素和阿糖胞苷在治疗急性髓性白血病或贫血时是否与盐酸佐苏魁地尔联合使用更有效尚不清楚。这项随机III期试验正在研究在治疗新诊断的急性髓性白血病或贫血的老年患者时，与单用柔红霉素和阿糖胞苷相比，盐酸佐苏quidar联合使用柔红霉素和阿糖胞苷的效果如何。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed. (from www.cancer.gov website) Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar trihydrochloride in treating acute myeloid leukemia or anemia. This randomized phase III trial is studying how well giving zosuquidar trihydrochloride together with daunorubicin and cytarabine works compared to daunorubicin and cytarabine alone in treating older patients with newly diagnosed acute myeloid leukemia or anemia that has not responded to previous treatment.